Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Union Chamber Calls For Market Opening, Equal Access In China; €1 Trillion In WTO Procurement At Stake

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Nearly a decade after joining the World Trade Organization, which requires all members to provide unfettered access to national markets and equal treatment to foreign and domestic business competitors, China is falling short across many areas, according to the leaders of the European Union Chamber of Commerce in China

You may also be interested in...



Sweating The Little Things: European Companies Call On China to Overhaul Public Procurement System

They say misery loves company, so in one respect, biopharma and medical device companies can rest easy knowing that firms in seemingly every industry, from information technology firms to wind power equipment manufacturers, are struggling to make heads or tails of China's estimated $1 trillion public procurement market

Sweating The Little Things: European Companies Call On China to Overhaul Public Procurement System

They say misery loves company, so in one respect, biopharma and medical device companies can rest easy knowing that firms in seemingly every industry, from information technology firms to wind power equipment manufacturers, are struggling to make heads or tails of China's estimated $1 trillion public procurement market

China's Delays In Approving Clinical Trials, Poor IPR Block Access To Innovative Drugs - EU Chamber Of Commerce

BEIJING - China's lengthy process in reviewing clinical trial applications, unpredictable schedule for updating the national catalog of reimbursable drugs, and lax protection of intellectual property rights are all blocking access for most Chinese citizens to the latest innovative medicines developed worldwide, according to a leader in the European Union Chamber of Commerce in China

Related Content

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel